Drugs and patents in ATC class L01DA

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
COSMEGEN	dactinomycin
DACTINOMYCIN	dactinomycin
>Tradename	>Generic Name

Last updated: June 11, 2026

Actinomycines in ATC L01DA are dominated by older cytotoxics, with market access and competition shaped more by patent-for-formulation, manufacturing process, and supply stability than by long-lived primary composition IP. For most meaningful products in this ATC class, the core active-substance patents have largely expired; remaining IP usually sits in Orange Book-listed formulation and method-of-use patents (for small molecules) or in biologic-adjacent manufacturing/process IP where applicable. As a result, “market dynamics” in L01DA are driven by: (1) limited global suppliers and intermittent shortages, (2) payer and hospital substitution behavior for generics, and (3) litigation around discrete generic entry triggers rather than sweeping reblocking of the active ingredient.

What actinomycines are included in ATC L01DA and how is the market structured?

ATC L01DA is the actinomycines class within antineoplastic agents. In practice, the commercially relevant products in this space are largely legacy injectable cytotoxics, with compendial demand concentrated in oncology protocols, supportive care pathways, and inpatient chemotherapy settings.

Which active ingredients typically drive L01DA demand?

The major active ingredient associated with actinomycines in oncology is:

Dactinomycin (actinomycin D)

In many markets, dactinomycin is available in generic form, with branded supply historically tied to original manufacturers and later distributed through generic entrants, contract manufacturing networks, and hospital formularies.

How do hospital procurement and shortage dynamics change the competitive picture?

For legacy injectables like actinomycines:

Switching is operationally easier than for complex injectables if labeling, dosing, and reconstitution instructions match.
Tender cycles and contract pharmacies can delay substitution even when patents expire.
Drug shortages and allocative purchasing shift bargaining power toward whichever supplier is available, regardless of patent status.
When product is scarce, exclusivity disputes matter less than supply continuity.

What is the commercial center of gravity?

Wholesaler availability and manufacturing yield are often the limiting factors.
Regulatory maintainability (manufacturing changes, sterile process validation, stability) can function like a practical barrier even when IP is weak.

What patents protect dactinomycin (actinomycin D) and related actinomycines in major markets?

How to think about actinomycine patent coverage

For older cytotoxics:

Primary composition-of-matter coverage is typically long expired.
Patent attention shifts to:
1. Sterile lyophilized formulation (excipients, stabilizers, particle control, reconstitution characteristics)
2. Container-closure system and compatibility (glass type, stopper materials)
3. Manufacturing process (sterile filtration/aseptic fill steps, lyophilization cycle parameters)
4. Method-of-use (dose regimens, pediatric protocols, specific indications)
5. Labeling-linked patents (if tied to a particular therapeutic claim or dosing)

H3: Which patent fields are most likely to appear in Orange Book practice for injectables?

Formulation patents for sterile injectables
Method-of-use patents tied to dosing regimens in oncology
Process patents for manufacturing and control

H3: Jurisdictional pattern for actinomycines

US: Orange Book lists drive entry timing for ANDA filers for small-molecule injectables
Europe: national marketing authorization dossiers can be updated with generics once local exclusivities end
UK/Canada: entry timing is governed by local regulatory frameworks plus patent enforcement in national courts
China/India: entry timelines often hinge on local filing and any patent enforcement actions, but the structural fact remains that composition IP is typically not the constraint

When does dactinomycin lose exclusivity in the US, and what are the practical entry timelines for generics?

For legacy cytotoxics, the critical timing is usually not “new” exclusivity grant dates but the absence or expiration of:

Orphan drug exclusivity (where it applies; many oncology drugs are not orphan in the US)
5-year new chemical entity (NCE) exclusivity (for older drugs it is not relevant)
3-year new clinical investigation exclusivity (rare for legacy)
Patent-protected listed patents in Orange Book

Generic entry risk is usually concentrated in “listed patent” gaps

For actinomycines, the generic strategy typically depends on whether a would-be entrant can file:

Paragraph IV certifications against a listed patent that still has legal life, or
Section viii carve-outs where patents have already expired, or
No certification if there are no listed patents that require certification for the relevant strength/form

Because these drugs are older, the most frequent scenario is that the remaining Orange Book patents have little or no barrier or are narrowly tied to specific formulations or dosage forms. When barriers remain, they tend to be formulation-specific, which pushes entrants into:

alternative strengths
alternative presentations
reformulation approaches that avoid infringement while maintaining label equivalence

What is the Orange Book status of dactinomycin and other actinomycines?

Orange Book status is the decisive checklist for US-based generic timing. For L01DA drugs, the general pattern is:

older actinomycines often have limited or expired listed patents
any active listings, when present, are typically formulation or method-of-use patents that can be defeated via design-around or non-infringement positions

If an Orange Book listing exists for a given strength and dosage form, it usually requires the ANDA filer to address it through the statutory certification pathway. The consequence is visible in filing behavior: entrants cluster where certification burdens are lower.

How many patents cover actinomycines, and which assignees dominate the estate?

In legacy oncology injectables, the patent landscape is usually:

small estate on active ingredient
narrower tail around formulations and manufacturing

Dominance is often held by:

original NDA holders and their patent arms
formulation-focused specialty pharma owners if they acquired product rights or obtained improvement patents
contract manufacturing groups if they pursued process IP

A full “how many patents” count depends on the specific strength, dosage form, and territory. For L01DA as a class, the actionable takeaway is that the estate is typically not broad at the molecule level and rarely blocks entry if the US market is already populated with generics.

Which companies have challenged dactinomycin patents via Paragraph IV ANDA litigation?

For old injectables in oncology, Paragraph IV litigation, when it occurs, is concentrated around:

the existence of a still-active Orange Book patent
narrow formulation/process claims
local market exclusivity strategies tied to hospital contracts

The common dynamic is that generics challenge only when there is a real entry delay risk; otherwise, they wait out listed patents. This pattern is typical for legacy oncology injectables where composition IP is expired.

What patent litigation affects actinomycines, and how have settlements shaped generic entry?

Settlement dynamics in legacy oncology injectables often follow two patterns:

Early-stage settlement with delayed launch
- A generic accepts a limited exclusivity-like runway.
- Consideration is frequently structured as a payment and/or market allocation.
- Patent validity is not always conceded, but entry dates are enforced contractually.
Non-infringement design-around that preserves a faster launch
- The generic changes formulation parameters, manufacturing steps, or container-closure details.
- Entry timing becomes a function of FDA comparability and label maintenance rather than the court outcome.

Because actinomycines are sterile injectables, process parameters and reconstitution behavior can be central to infringement analysis.

What formulations are protected for actinomycines, and where are generic design-around paths most viable?

H3: Formulation hotspots that create IP friction

excipient selection (stabilizers)
lyophilization cycle and residual moisture control
reconstitution time and solubility behavior
container-closure compatibility

H3: Process hotspots

sterile filtration or aseptic fill parameters
sterilization of components
lyophilization endpoint criteria
in-process controls for potency and impurity profile

Generic design-around viability

Design-around is most viable where:

the claims are narrow and tied to specific formulation parameters
the competitor can meet reference product specs under a different manufacturing route
any method-of-use claims are absent from the reference label scope

For method-of-use claims, the controlling question becomes whether the generic label design omits the patented regimen or whether a carve-out can be maintained through FDA labeling rules.

How does actinomycin D compare with other actinomycines in terms of patent and market barriers?

Within ATC L01DA, the practical difference is not whether actinomycines exist as a class, but whether there is:

a marketed product with active listed patents
a supply-constrained niche that maintains pricing power
an implemented manufacturing base that reduces barrier-to-entry for generics

In most markets, the biggest practical barrier is supply continuity rather than broad patent exclusivity. As a result, competitive outcomes can be driven by manufacturing readiness and regulatory chemistry controls.

What FDA pathways matter for actinomycines, and what generic entry risks exist?

ANDA for small-molecule injectables

Actinomycines like dactinomycin are typically handled via ANDA pathways (for generic equivalents) under the Hatch-Waxman framework.

Generic entry risks:

Patent certification risk (Paragraph IV vs carve-outs vs expiration)
Suitability risk (sterile manufacturing compliance)
Product-specific risks (stability, potency, impurity profile alignment)

Labeling and method-of-use risk

If method-of-use patents are listed and tied to labeled indications or dosing regimens, generic entry can be delayed by labeling design issues even when composition IP is expired.

What manufacturing/IP barriers most commonly delay generic actinomycin launches?

For sterile cytotoxics:

process validation burden increases with any change to lyophilization parameters or reconstitution requirements
potency and impurity specifications are tighter for older cytotoxics due to protocol sensitivity
container-closure compatibility can require bridging studies
supplier qualification in aseptic facilities can be a bottleneck

In practice, even when patents are not enforceable or have expired, the operational barrier can slow entry enough to shift market dynamics.

Revenue exposure: how much of the market is likely protected by patents versus supply and competition?

For L01DA as a class:

patent tail risk is typically concentrated in a small number of listed patents tied to specific presentations
the largest revenue sensitivity is often supply-related rather than legal exclusivity

High-leverage exposures for business decisions:

whether a still-listed patent blocks a new generic entrant in the next 12 to 36 months
whether a competitor can switch to an alternative strength/container quickly enough to win hospital tenders

Key Takeaways

L01DA actinomycines are largely legacy injectables where composition-of-matter exclusivity has mostly expired, leaving a narrower tail in formulation, container-closure, process, and sometimes method-of-use patents.
Market dynamics are shaped more by supply continuity, hospital procurement cycles, and sterile manufacturing capability than by broad ongoing exclusivity.
Where patent barriers persist, they are typically Orange Book listed and formulation- or presentation-specific, making generic entry most vulnerable to narrow patent claims rather than molecule-level exclusivity.
Litigation and settlements, when they occur, usually focus on discrete listed patents and can translate into launch timing delays or design-around outcomes.

FAQs

1) What types of patents are most common for legacy injectable actinomycines like dactinomycin?
Formulation (sterile composition, excipients, lyophilized attributes), container-closure compatibility, manufacturing process, and sometimes method-of-use tied to labeled dosing regimens.

2) How do Paragraph IV challenges typically affect generic launch timing for older oncology injectables?
They trigger 30-month stay risk when a still-listed patent is attacked unsuccessfully or the case timing extends; if patents are expired or claims are narrow, entrants often proceed with faster launches.

3) What are the most likely design-around levers for actinomycin formulations?
Changing formulation parameters within claimed ranges, altering manufacturing lyophilization endpoints, and selecting different container-closure configurations while maintaining reference product critical quality attributes.

4) Do actinomycines face biosimilar-like competition risk?
No, actinomycines are small-molecule cytotoxics; the competitive framework is generics via ANDA rather than biosimilars.

5) What practical factors can delay generic entry even after patents expire?
Sterile process validation and comparability bridging for potency/impurity profiles, container-closure compatibility work, and hospital tender/contract switching cycles.

References (APA)

U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
World Health Organization. (n.d.). ATC classification system. WHO. https://www.who.int/tools/atc-ddd-toolkit/atc-classification
U.S. Code. (n.d.). Hatch-Waxman Amendments and statutory provisions governing ANDAs and patent certifications (21 U.S.C. §355). Legal Information Institute. https://www.law.cornell.edu/uscsection/21/355

Drugs in ATC Class L01DA

Drugs in ATC Class: L01DA - Actinomycines

Market dynamics and patent landscape for ATC Class L01DA (Actinomycines): who holds exclusivity, what patents matter, and where generic and biosimilar risk concentrates